Heidelberg Pharma AG (FRA:HPHA)
4.400
+0.260 (6.28%)
Aug 13, 2025, 4:00 PM EDT
Heidelberg Pharma AG Revenue
Heidelberg Pharma AG had revenue of 118.51K EUR in the quarter ending May 31, 2025, a decrease of -95.75%. This brings the company's revenue in the last twelve months to 4.18M, down -56.07% year-over-year. In the fiscal year ending November 30, 2024, Heidelberg Pharma AG had annual revenue of 6.85M, down -30.53%.
Revenue (ttm)
4.18M
Revenue Growth
-56.07%
P/S Ratio
47.68
Revenue / Employee
37.69K
Employees
105
Market Cap
199.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 6.85M | -3.01M | -30.53% |
Nov 30, 2023 | 9.86M | -8.66M | -46.75% |
Nov 30, 2022 | 18.51M | 16.48M | 810.30% |
Nov 30, 2021 | 2.03M | -6.63M | -76.53% |
Nov 30, 2020 | 8.67M | 1.17M | 15.63% |
Nov 30, 2019 | Pro | Pro | Pro |
Nov 30, 2018 | Pro | Pro | Pro |
Nov 30, 2017 | Pro | Pro | Pro |
Nov 30, 2016 | Pro | Pro | Pro |
Nov 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Siemens Energy AG | 38.39B |
Rheinmetall AG | 10.67B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Heidelberg Pharma AG News
- 15 days ago - EQS-NVR: Heidelberg Pharma AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 22 days ago - EQS-DD: Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares through the exercise of 90,000 stock options under the 2011 stock option program (tranche 2; issue 2016) for ... - Wallstreet:Online
- 5 weeks ago - EQS-News: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business - Wallstreet:Online
- 3 months ago - EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board - Wallstreet:Online
- 3 months ago - EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025 - Wallstreet:Online
- 4 months ago - EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025 - Wallstreet:Online
- 5 months ago - EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 - Wallstreet:Online